Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New taper strategy aims to free PMR patients from Long-Term steroids

NCT ID NCT05636501

Disease control Sponsor: Aarhus University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a nurse-led, step-by-step plan to slowly reduce prednisolone (a steroid) helps people with polymyalgia rheumatica stop the drug safely and stay in remission. About 120 newly diagnosed patients will either follow this structured taper or receive usual care from their general practitioner. The goal is to see if the structured approach leads to more patients being off steroids and symptom-free after one year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2023

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients newly diagnosed with PMR according to the EULAR criteria for PMR. * No sign of GCA on ultrasonography of the temporal and axillary arteries. * Age over 50 years. * Danish spoken and written language skills sufficient to fill out questionnaires. Exclusion Criteria: * Peroral, intraarticular or intramuscular application of glucocorticoids within the last month. * Previous prednisolone treatment for GCA/PMR. * Unable to give consent. * Symptoms of GCA (newly onset-headache, tenderness of the temporal artery, jaw claudication, vision disturbances). * Active malignant cancers within the last 5 years (except basal cell carcinoma). * Other inflammatory rheumatic diseases (eg. rheumatoid arthritis, polymyositis, spondyloarthritis, psoriatic arthritits, gout). * Uncontrolled diseases (eg severe active asthma, cardiac disease with NYHA class IV)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Polymyalgia rheumatica are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

polymyalgia rheumatica

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Polymyalgia rheumatica

Contacts and locations

Locations

  • Aalborg University Hospital

    Aalborg, Denmark

  • Aarhus University Hospital, Department of Rheumatology

    Aarhus, Denmark

  • Gødstrup Regional Hospital

    Herning, Denmark

  • Hjørring Regional Hospital

    Hjørring, Denmark

  • Horsens Regional Hospital

    Horsens, Denmark

  • Silkeborg Regional Hospital

    Silkeborg, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.